Executive Summary

Crane NXT (CXT) delivered Q4 2025 results that expose a widening gap between business fundamentals and market valuation. The company reported 20 micro-optics denomination wins in 2025 versus a 10-15 target, with 11 wins in Q4 alone showing clear acceleration. International currency backlog is up over 50% year-over-year. The US $10 bill redesign equipment is installed and ready, with Treasury unveiling expected mid-2026.

The stock trades at $52.76 — 11.16x forward P/E on $4.25 midpoint EPS guidance — while sitting at 41% of its 52-week range. Analyst consensus target is $74 (+40%). Short interest stands at 14.9% of float with 12.3 days to cover.

Management is investing aggressively: moving to 24/7 operations, adding production lines in Nashua and Malta, raising CapEx to 7% of currency revenue. They cite three structural drivers for international demand: increased counterfeiting in emerging markets, economic growth coupled with inflation, and accelerating currency redesign cycles globally.

The setup: Investor Day on February 25 in New York. If management articulates the multi-year international opportunity clearly, this re-rates. The short interest amplifies the mechanics.

Key risk: Margin compression from capacity investments is real. SAT segment margins fell 420 basis points in Q4 from mix, FX headwinds, and scaling costs. Management guides 120 basis points improvement in 2026, but full benefit arrives in 2027+.

Financial Performance

Q4 2025:

  • Revenue: $477M (+20% YoY, +5% core)
  • Adjusted EBITDA margin: ≈26% (-120 bps YoY)
  • Adjusted EPS: $1.27
  • Free cash flow conversion: 135%

Full Year 2025:

  • Revenue: $1.7B (+11% YoY, +1% core)
  • Adjusted EBITDA margin: ≈24% (-260 bps YoY)
  • Adjusted EPS: $4.06
  • Free cash flow conversion: 94%

2026 Guidance:

  • Revenue growth: 4-6%
  • Adjusted EBITDA margin: ≈28% (flat YoY)
  • EPS: $4.10-$4.40
  • FCF conversion: 90-110%
  • Net leverage: 2.3x
  • Dividend increased 6%

Revenue phasing skews second half. Q1 expected up mid-teens driven by SAT (+45-50% from De La Rue acquisition and full US currency operations), partially offset by mid-single-digit CPI decline from hardware timing.

International Currency: The Core Thesis

What happened in 2025:

CXT secured 20 new micro-optics denomination wins, exceeding the 10-15 target range. Eleven wins came in Q4 alone. Organic backlog is up over 30% year-over-year, with SAT backlog up over 50%.

CEO Aaron Saak on the Q4 call: "I am more positive than we ever thought we would feel versus two years ago based on what we see in the market."

Notable wins include five denominations for Fiji featuring micro-optics integrated into polymer substrates (first polymer integration), and a security-only contract with a Latin American country (highest-margin business model, customer unnamed due to contract restrictions).

Why it's accelerating:

Management cited three structural drivers:

  1. Increased counterfeiting in emerging markets forcing currency redesigns with higher security features. CXT has the leading micro-optics technology and wins naturally when security upgrades.

  2. Economic growth and inflation in emerging markets. CXT's international business is predominantly emerging market-focused. Growth + inflation = more currency demand.

  3. Faster redesign cycles globally. When one country redesigns, neighboring countries follow. The upcoming US redesign (new $10 bill mid-2026) accelerates this dynamic as new security features become visible globally.

Saak: "We see all three of these — from increased counterfeiting, growth in emerging economies, and faster redesign times — as durable trends in this currency business."

Capacity response:

CXT is moving micro-optics and banknote printing to 24/7 operations (from 24/5), expected complete by end of Q1 2026. Adding a new production line in Nashua, NH. Expanding Malta facility for European/emerging market proximity and operational redundancy.

CapEx rising to ≈7% of currency revenue in 2026 (normally 3-5%). Additional $4M OpEx for product development and capacity expansion.

Near-term margin pressure is real. SAT adjusted operating margin fell 420 basis points in Q4 from unfavorable mix (specific shipments from backlog), higher costs to meet demand (hiring, training, freight, third-party substrates, outsourced banknote printing), and FX headwinds (manufacturing costs in Sweden/Malta denominated in SEK/EUR).

Management guides 120 basis points EBITDA margin improvement in SAT for 2026 (to ≈25%), with continued incremental improvement thereafter as internal productivity programs execute and capacity investments scale.

CFO Christina Cristiano: "We are very focused on ensuring we are maximizing our value and the pricing power we have with our leading technology."

This is not a book-and-ship business. Contracts enter backlog well before delivery, providing visibility. The 50% backlog growth is the leading indicator.

US Currency Redesign: Near-Term Catalyst

CXT completed final equipment upgrades in 2025 to support the new US currency series. The new $10 bill is expected to release later in 2026, with US Treasury design unveiling likely mid-2026.

From the transcript: "Final equipment upgrades to support the launch of the new U.S. currency series... preparing for the release of the new $10 bill later this year."

This is a multi-year revenue cycle. When the US redesigns currency, Crane NXT supplies security features and testing equipment. The company has a captive supplier relationship with the US government.

2026 guidance includes "high single-digit growth U.S. Currency favorable mix" — management expects mix benefit as the new bill ramps.

The unveiling mid-2026 is a discrete catalyst. The market will see the security features (likely including CXT's micro-optics technology), and the multi-year revenue cycle becomes tangible.

Antares Vision: Expanding TAM

CXT closed its initial ≈32% equity stake in Antares Vision in Q4 2025. Italian regulatory approval secured. Mandatory tender offer launching February 2026, with expectation to own >50% by end of Q1 and consolidate results.

Voting agreements with largest shareholders ensure ability to take the company private, expected mid-2026.

Antares Vision is a global leader in advanced detection systems and track-and-trace software for life sciences and food/beverage. This expands CXT's TAM beyond currency into authentication and traceability for higher-growth end markets.

Management will update 2026 guidance to include Antares Vision consolidation with Q1 earnings in May.

The strategic logic: CXT already leads in currency authentication. Antares Vision extends that capability into consumables with regulatory traceability requirements (pharma serialization, food safety). Cross-sell opportunities across customer bases.

Execution risk exists. Taking an Italian public company private, integrating cross-border operations, and scaling a new vertical while managing currency capacity expansion is real. Beta at 1.33 means market volatility amplifies downside.

Crane Authentication: Margin Inflection

CXT combined OPSX Security and De La Rue Authentication into a single integrated business in 2025. The De La Rue acquisition closed in May.

Key wins: renewed multiyear NFL contract for physical product authentication and online brand protection, signed multiyear MLB agreement in Q4 for security technology on consumer products.

These are sticky, recurring revenue relationships with globally recognized brands. Once embedded in authentication and licensee management software, customers rarely switch.

Management executed 80/20 initiatives driving synergy realization ahead of schedule. Guidance expects "significant margin accretion" in 2026.

This business contributed as expected in Q4, with full-year 2026 guidance including mid-single-digit core growth.

CPI: Stable Cash Generator

Payment and merchandising technologies segment (CPI) reported flat Q4 core sales, with double-digit gaming growth offset by vending softness from indirect tariff impact.

Full-year 2025 core sales down ≈4% as pricing actions to offset tariffs caused customer order delays in vending.

Despite revenue headwinds, CPI maintained ≈29% adjusted operating margin for the year through disciplined cost management and productivity. Q4 margin expanded 340 basis points to ≈32%.

2026 guidance: flat revenue, 30% EBITDA margin, strong free cash flow conversion.

Breakdown: mid-single-digit service growth (expanding offering), approximately flat hardware, low single-digit vending decline (tariff headwinds persist).

This segment is a stable cash generator funding growth investments in SAT.

Valuation and Technical Setup

Current valuation:

  • Price: $52.76
  • Forward P/E: 11.16x (on $4.25 midpoint guidance)
  • Market cap: $3.0B
  • Analyst consensus target: $74.17 (+40%)
  • Target range: $58-$85

Momentum:

  • 1-year: -10.7%
  • 52-week range: $41.54 - $69.00 (currently at 41%)
  • RSI (14D): 57.2
  • Below 200-day MA ($56.87)

Short interest:

  • 14.9% of float
  • 12.3 days to cover

Options market:

  • ATM IV: 75.6% (145th percentile vs 52-week range 24-60%)
  • P/C ratio: 0.60 (bullish tilt)
  • Max pain: $50 (5.2% below current)

Interpretation:

Options market is pricing event risk ahead of Investor Day (Feb 25). IV at 145th percentile means option premium is expensive — equity is the right vehicle if sizing this.

Short interest at 14.9% with 12.3 days to cover creates squeeze potential if fundamentals continue to deliver. Shorts cannot exit quickly on positive sentiment shift.

The stock is down 11% over the past year while backlog grew 50%, wins accelerated to 20 (vs 10-15 target), and management raised capacity investments based on structural demand drivers. The disconnect is the setup.

Beta at 1.33 means market drawdown hits this hard. Not a defensive position.

What the Worldview Already Knew

This is the first CXT coverage in the worldview. No prior evidence, predictions, or scenarios existed.

Cross-ticker context: No direct comps in currency security micro-optics (CXT has near-monopoly positioning). Adjacent authentication/traceability exposure via Antares Vision overlaps with serialization/track-and-trace in pharma (companies like LAKE, TTEK) but different business models.

The international currency thesis is idiosyncratic to CXT. The capacity expansion, US $10 bill catalyst, and Investor Day timing are company-specific.

What Matters Going Forward

Catalyst timeline:

  • Feb 25, 2026: Investor Day in New York. Management will present strategy, growth opportunities, and financial priorities, including showcasing advanced technologies.
  • Mid-2026: US Treasury unveiling of new $10 bill design.
  • Late 2026: New $10 bill release.
  • May 2026: Q1 earnings with updated guidance including Antares Vision consolidation.

Key questions:

  1. Can management articulate the multi-year international currency opportunity clearly at Investor Day? If yes, this re-rates.
  2. Does the US $10 bill design showcase CXT's micro-optics technology visibly? Public unveiling creates tangible validation.
  3. Do margins inflect in 2026 as guided (120 bps improvement in SAT)? Or does capacity investment + FX pressure persist longer?
  4. Does Antares Vision integration execute smoothly? Cross-border take-private adds complexity.

Bull case:

  • 20 wins vs 10-15 target proves durable demand
  • 50% backlog growth is leading indicator, not lagging
  • Capacity investments position for multi-year growth cycle
  • US $10 bill catalyst is concrete and near-term
  • Antares Vision expands TAM into higher-growth verticals
  • Stock at 11x forward while business accelerates = mispricing
  • Short interest (14.9%, 12.3 DTC) amplifies upside on re-rating

Bear case:

  • Margin compression persists through 2026 (market impatient)
  • Antares Vision integration stumbles (execution risk, leverage)
  • International wins were pull-forward, not sustainable acceleration
  • FX headwinds worsen (EUR/SEK manufacturing costs)
  • Tariff impact on CPI worsens (vending decline accelerates)
  • Market multiple contracts (beta 1.33 means CXT falls harder)

Conclusion

CXT is a $3B market cap currency security supplier with near-monopoly micro-optics technology, trading at 11x forward earnings while business fundamentals accelerate. International wins doubled the target range, backlog is up 50%, and management is investing for sustained growth.

The setup: Investor Day February 25, US $10 bill unveiling mid-2026, 14.9% short interest with 12+ days to cover.

The risk: Margin pressure from capacity investments and Antares Vision execution.

If you believe the three structural drivers (counterfeiting, emerging market growth, faster redesign cycles) are durable, and management can articulate that at Investor Day, this re-rates. The short squeeze mechanics add fuel.

If you think the wins were a pull-forward and margins stay compressed, pass.

The stock is near 52-week lows. The business is arguably at multi-year highs. That's the disconnect.